GRAL · NASDAQ · Medical - Diagnostics & Research

GRAIL (GRAL)

Developer of Galleri and targeted methylation tools for cancer detection.

$108.52
vs last close+0.55 (+0.51%)

Something off on this page? Send us feedback.

Next report
Nov 11, 26
in 49 days
EPS estimate
−$2.51
Revenue estimate
$44.3M
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$2.89−$3.10−$3.18−$2.46−$2.44−$2.29−$2.56Pending
Estimate−$4.41−$4.03−$3.14−$3.36−$3.33−$2.76−$2.66−$2.51
Surprise+34.5%+23.1%−1.3%+26.8%+26.7%+17.1%+3.8%

RevenueReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$38.3M$31.8M$35.5M$36.2M$43.6M$40.8M$44.7MPending
Estimate$34.4M$35.2M$34.1M$34.6M$43.6M$39.2M$42.4M$44.3M
Surprise+11.2%−9.6%+4.2%+4.6%0.0%+4.2%+5.4%

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2028−$2.32
Sep 2028−$2.22
Jun 2028−$2.47
Mar 2028−$2.34
Dec 2027−$2.75
Sep 2027−$2.76
Jun 2027−$2.64
Mar 2027−$2.69
Dec 2026−$2.50
Nov 2026−$2.51
Aug 2026−$2.66−$2.56+3.8%
May 2026−$2.76−$2.29+17.1%
Feb 2026−$3.33−$2.44+26.7%
Nov 2025−$3.36−$2.46+26.8%
Aug 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
Mar 2024
Dec 2023
Sep 2023
Jun 2023
Apr 2023
Sep 2020
Sep 2019

The latest year is open to everyone — the 12 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2028−$2.32$71.6M
Sep 2028−$2.22$61.6M
Jun 2028−$2.47$61.8M
Mar 2028−$2.34$56.9M
Dec 2027−$2.75$64.7M
Sep 2027−$2.76$55.7M
Jun 2027−$2.64$55.4M
Mar 2027−$2.69$48.8M
Dec 2026−$2.50$51.2M
Nov 11, 2026−$2.51$44.3M
Aug 5, 2026−$2.66−$2.56+3.8%$42.4M$44.7M+5.4%−14.5%
May 5, 2026−$2.76−$2.29+17.1%$39.2M$40.8M+4.2%+15.4%
Feb 19, 2026−$3.33−$2.44+26.7%$43.6M$43.6M0.0%−50.6%
Nov 12, 2025−$3.36−$2.46+26.8%$34.6M$36.2M+4.6%−1.9%
Aug 12, 2025
May 13, 2025
Feb 20, 2025
Nov 12, 2024
Aug 13, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023
Jun 29, 2023
Apr 2, 2023
Sep 29, 2020
Sep 29, 2019

The latest year is open to everyone — the 12 quarters behind it read with an account.